Pan-fungal vaccine NXT-2 elicits robust immunity without disrupting gut microbiome in macaques
Background
Invasive fungal infections pose a severe public health threat, causing high mortality and morbidity, especially in at-risk populations. Current therapeutic options are limited, face increasing drug resistance, and new pathogens are emerging, yet no approved fungal vaccines exist. The gut mycobiome's role in immunity, including its implication in conditions like inflammatory bowel disease (IBD), highlights the need for interventions that protect against fungal pathogens without disrupting beneficial microbial communities. This study addresses the critical gap in developing safe and effective antifungal vaccines.
Study Design
Researchers evaluated the impact of immunization with the NXT-2 vaccine candidate in Japanese and rhesus macaque cohorts. NXT-2 is a 90 amino acid consensus peptide derived from a conserved fungal antigen, KEX1. They monitored changes in the gut mycobiome and microbiome pre- and post-vaccination. Gut mycobiome analysis was performed using ITS2 sequencing, while the microbiome was assessed via metagenomic sequencing. The primary endpoints included changes in microbial diversity (alpha and beta), taxonomic composition, and functional capacity, alongside assessment of antibody response.
Results
Immunization with NXT-2 elicited a robust antibody response in both Japanese and rhesus macaque species. Crucially, this protective immunity was achieved without disrupting the gut microbial communities. The mycobiome demonstrated remarkable stability, showing no significant changes in alpha and beta diversity, taxonomic composition, or functional guild distributions. The relative abundance of gut resident Candida and Aspergillus species also remained stable and was not significantly altered following vaccination. Similarly, the microbiome exhibited stability with preserved alpha and beta diversities, taxonomic composition, and functional capacity. This represents the first cross-kingdom analysis demonstrating that antifungal vaccination can achieve protective immunity without perturbing gut microbial communities.
NXT-2 immunization generated a robust antibody response while maintaining complete stability of both gut mycobiome and microbiome diversity, composition, and function across two macaque species.
Key Findings
- NXT-2 immunization elicited a robust antibody response in both Japanese and rhesus macaques.
- The gut mycobiome showed no significant changes in alpha/beta diversity, taxonomic composition, or functional guilds post-vaccination.
- Relative abundance of gut Candida and Aspergillus species remained stable after NXT-2 vaccination.
- The gut microbiome maintained preserved alpha and beta diversities, taxonomic composition, and functional capacity.
Why It Matters
This study provides compelling evidence that a pan-fungal vaccine can induce protective immunity without causing collateral damage to the gut's beneficial microbial ecosystem. This establishes a crucial framework for developing safe, broad-spectrum antifungal vaccines that avoid disrupting the gut microbiome, a key consideration for patient health. For future vaccine development, this highlights the importance of microbiome-informed assessment beyond conventional immunogenicity and adverse effect monitoring. It suggests that next-generation antifungal strategies could offer robust protection while preserving gut health, potentially reducing risks associated with dysbiosis.
nxt-2
fungal-infection
vaccine
gut-microbiome
gut-mycobiome
non-human-primate